Articles On Race Oncology (ASX:RAC)

Cancer has long been one of the great evils of healthcare. It is easily one of the most insidious and prolific group of diseases society has dealt with. A burden that we are constantly struggling to find better ways to deal with. We are mak...

A quick wrap of the key winners and losers on Tuesday, June 16. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made potentially market-moving announcements during the day. The benchmark ASX200 Index bounced b...

Specialty pharmaceutical company Race Oncology (ASX: RAC) has reported positive data from an investigator-initiated Phase II clinical trial of historical cancer drug Bisantrene on patients with relapsed or refractory acute myeloid leukaemia...

The Race Oncology Ltd (ASX: RAC) share price has shot out of the gates this morning on the back of positive clinical trial results. Race Oncology shares opened 74.6% higher today and raced to an intra-day high of 60 cents in early trade –...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

The journey of each individual medical treatment from idea to market requires the involvement of multiple parties big and small. The general consensus seems to be that it takes a big player to get a drug to market, which more often than not...

The perception of cancer as one incurable disease is wrong, according to a director of one of the ASX’s most prominent cancer fighters. Phillip Lynch, who joined the board of Race Oncology (ASX:RAC) last week, says cancer is a war fought on...

Pre-revenue biotech and medtech companies are still not eligible for the Jobkeeper wage subsidy according to the ATO, a double whammy for a swathe of research-driven ASX businesses with large staff costs. The Jobkeeper program allows busine...

Despite March being a tough month to raise capital for ASX small caps, the money was still flowing for the gold explorers. In March, ASX small caps raised $72.2m, a steep decline from the $125m raised in February. Even in January, tradition...

Pharmaceutical company Race Oncology (ASX: RAC) has come out of a trading halt this morning to announce $1.8 million new equity funding via a strategic placement of 6 million shares. The $0.30 per share issue price represents a 9% discount...

Businesses will take any opportunity to cash in on a crisis and the latest move to profit from the coronavirus outbreak has been made by dietary supplement maker Eagle Health Holdings (ASX:EHH). After announcing it was partnering up with Zo...

With the health and life science sector being the ASX’s top performer last year, Western Australia is keen to join the party. The state government has formed an Industry Reference Group to come up with a five-year growth plan for the indust...

Race Oncology (RAC) has updated the market on its activities for the December 2019 quarter The company launched a 5-path clinical strategy for its cancer drug called Bisantrene Bisantrene is targeting cancers beyond Acute Myeloid Leukaemia...

The health sector was the most successful sector on the ASX in 2019. Various small caps made several breakthroughs including with nerve damage and macular degeneration. While cancer remains one fish that has yet to be fried there are small...

Every week Stockhead publishes a weekly column of directors trades of $100,000 or more among ASX small caps. As 2019 draws to a close, we thought we could re-cap the most noteworthy trades.   Biggest trade Wagners (ASX:WGN) co-founders Deni...

Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast. In this episode Tim chats with Race Oncology (ASX:RCE) CEO Peter Mol...

Last week was another quiet week among directors trades but a handful still made big trades (above $100,000). The biggest trader was once again Ian Gandel of Alliance Resources (ASX:AGS), this week buying $2.8 million. He has been on the co...

Race Oncology (ASX: RAC) has appointed Nucleics founder Dr Daniel Tillett to its board as chief scientific officer. Dr Tillett is the founder and chief executive officer of Australian biotechnology company Nucleics, which develops DNA seque...

Last week appeared to be a good time to buy, judging by the number of trades above $100,000; but two directors not only couldn’t buy, but had to sell. Why? The Taxman. Kogan’s (ASX:KGN) Harry Debney sold nearly $1m of stock to pay a tax bi...

Here’s our fortnightly wrap of all the news driving ASX small cap health stocks. We last checked in with ASX small cap health stocks just hours after Opthea’s (ASX:OPT) anti macular degeneration drug passed a large clinical test with flying...

Digital healthcare service has evolved as one of the fastest-growing industries in the modern era. Introduction of technology in medical science has emerged as one of the biggest blessings for human. Digitally connected network systems have...

The funding will be used to advance clinical projects for Race’s cancer drug Bisantrene.

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Race Oncology (ASX:RAC) has announced the successful completion of a $1.45 million placement, led by biotechnology investor Dr Daniel Tillett.

On Stockhead today, the disconnect between federal and state governments on coal, private equity deals are rising and an ‘avalanche’ is laying waste to lithium prices. But first, here’s what you need to know.   The day ahead Data Today the...

On Stockhead today, investors should fall back in love with junior explorers once tech and cannabis lose their appeal, Opthea may need a bit of cash but it’s recent success has put it in a strong position, and Antler has invested $1.2m in p...

A one-day gain of 148 per cent has Opthea as comfortably the best-performing small cap health or biotech stock on the ASX at a time when the majority are trending downwards. Stockhead reported today on Opthea’s (ASX:OPT) positive results fr...

Rare cancers can hurt every bit as much as more common cancers, but as it happens, they’re often too rare to present a target market for big pharmaceuticals. One of these rare cancers is myelogenous leukemia and a drug being put to the test...

The pharmaceutical market in Australia is defined as a knowledge-intensive, technology-driven industry that is well poised to contribute to the overall economic activity and particularly enhance social wellbeing. The S&P/ASX 200 Health...

Remember Orthocell (ASX: OCC), that company gained 377 per cent in a day when it showed Cel-Gro helped patients with nerve damage regain sensation? It could be even more powerful than it showed then. While indeed, the trial showed it helpe...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. The market opens at 10am (eastern time) and the data is taken at 10:15am, once every stock has commenced trading. Stocks highlighted in yel...

“This is a major milestone for Race, because it’s the first treatment with Bisantrene since the drug disappeared more than 25 years ago,” said CEO Peter Molloy.

In this week’s recap of substantial holder movements four substantial holders bought shares in Zenith Energy (ASX:ZEN), a Shanghai investor bought into Anson Resources (ASX:ASN) and Sirtex’s founder bought into Syrah Resources (ASX:SYR). Su...